Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.8K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.8K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

10.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.2K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

2.0K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

2.1K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients with lymphatic malformations who receive the immunostimulant OK-432 experience excellent long-term outcomes.

Acta paediatrica (Oslo, Norway : 1992)·2015
Same author

New lipophilic terbutaline ester prodrugs with long effect duration.

Pharmaceutical research·2013
Same author

The crystallography beamline I711 at MAX II.

Journal of synchrotron radiation·2006
Same author

Cooperative zinc binding in a staphylococcal enterotoxin A mutant mimics the SEA-MHC class II interaction.

Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry·2001
Same author

Prevalence of cdtABC genes encoding cytolethal distending toxin among Haemophilus ducreyi and Actinobacillus actinomycetemcomitans strains.

Journal of medical microbiology·2001
Same author

Symmetrical stabilization of bound Ca2+ ions in a cooperative pair of EF-hands through hydrogen bonding of coordinating water molecules in calbindin D(9k).

Biochemistry·2001

Related Experiment Video

Updated: May 5, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

13.5K

Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs.

L A Svensson1

  • 1, .

Pharmaceutical Research
|November 26, 2013
PubMed
Summary

Developing selective bronchodilator beta2-adrenoceptor agonists is crucial for respiratory conditions. A prodrug pharmacokinetic approach shows promise for lung-selective drugs with fewer side effects than pharmacodynamic methods.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

Related Experiment Videos

Last Updated: May 5, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

13.5K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Selective bronchodilator beta2-adrenoceptor agonists are key for managing respiratory diseases.
  • Current pharmacodynamic approaches yield high beta2-adrenoceptor specificity but cause side effects like tremor and palpitations.
  • Beta2-adrenoceptors in airways, skeletal muscle, and blood vessels are pharmacologically similar, complicating selectivity.

Purpose of the Study:

  • To review the development of selective bronchodilator beta2-adrenoceptor agonists.
  • To compare pharmacodynamic and pharmacokinetic strategies for achieving lung selectivity.
  • To evaluate the potential of prodrugs for reducing side effects.

Main Methods:

  • Review of pharmacodynamic approaches targeting beta2-adrenoceptor specificity.
  • Analysis of pharmacokinetic approaches converting existing agonists into lung-selective prodrugs.
  • Assessment of drug selectivity and side effect profiles.

Main Results:

  • Pharmacodynamic approaches achieve high beta2-adrenoceptor specificity but retain side effects.
  • Side effects are attributed to the indistinguishable nature of beta2-adrenoceptors in different tissues.
  • The prodrug pharmacokinetic approach demonstrates potential for selective bronchodilation with reduced adverse effects.

Conclusions:

  • Pharmacodynamic strategies for selective bronchodilators have limitations due to receptor similarity.
  • The pharmacokinetic prodrug approach offers a promising avenue for developing safer, lung-selective bronchodilators.
  • Further research into prodrug strategies could significantly improve treatment outcomes for respiratory conditions.